Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity (TOLERASIT)

Eurofarma

Status: Withdrawn

Conditions: Overweight; Obesity

Treatments: Other: Source document data collection

Study type: Observational

Funder types: Industry

Identifiers

NCT05209997

EF179

Details and patient eligibility

About

An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with comorbidity(ies) or obesity. Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be included in the study.

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients
• Both sexes
• Diagnose of overweight with comorbidity(ies) or obesity
• Treatment use of sibutramine combined with topiramate
• Treatment prescription between 2011 and the beginning of the study

Exclusion criteria

• Use of topiramate for other condition besides overweight with comorbidity(ies) or obesity
• Individual use of one of the medications (sibutramine or topiramate)